Immunic (IMUX) News Today $1.06 -0.03 (-2.75%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Short Interest in Immunic, Inc. (NASDAQ:IMUX) Expands By 29.7%November 17 at 3:55 AM | americanbankingnews.comImmunic's IMU-856 shows potential in gastrointestinal health trials - ICYMINovember 16 at 12:59 PM | proactiveinvestors.comImmunic, Inc. (NASDAQ:IMUX) Short Interest UpdateImmunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 4,500,000 shares, a growth of 29.7% from the October 15th total of 3,470,000 shares. Based on an average daily trading volume, of 704,000 shares, the days-to-cover ratio is presently 6.4 days.November 15 at 9:08 AM | marketbeat.comRichard Alan Rudick Acquires 87,300 Shares of Immunic, Inc. (NASDAQ:IMUX) StockNovember 14 at 8:40 AM | insidertrades.comImmunic announces publication of IMU-856 dataNovember 13, 2024 | markets.businessinsider.comImmunic reports positive Phase 1 results for celiac disease therapy published in The LancetNovember 13, 2024 | proactiveinvestors.comImmunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyNovember 13, 2024 | prnewswire.comOptimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCaNovember 13, 2024 | markets.businessinsider.comImmunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial ChallengesNovember 9, 2024 | finance.yahoo.comImmunic, Inc. (IMUX) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comEQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 8, 2024 | markets.businessinsider.comImmunic, Inc. Advances MS Trials Amid Financial UpdateNovember 8, 2024 | markets.businessinsider.comImmunic highlights progress in multiple sclerosis programs, targets 2025 milestonesNovember 7, 2024 | proactiveinvestors.comImmunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | prnewswire.comImmunic Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comImmunic (IMUX) to Release Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comImmunic (IMUX) Scheduled to Post Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comImmunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate UpdateOctober 31, 2024 | prnewswire.comEQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in NovemberOctober 29, 2024 | markets.businessinsider.comImmunic to Participate in Industry, Scientific and Investor Conferences in NovemberOctober 29, 2024 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from BrokeragesImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has been given an average rating of "Buy" by the seven brokerages that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The aveOctober 29, 2024 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Sees Large Growth in Short InterestImmunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 3,470,000 shares, a growth of 29.5% from the September 30th total of 2,680,000 shares. Based on an average trading volume of 576,100 shares, the days-to-cover ratio is presently 6.0 days.October 28, 2024 | marketbeat.comPromising Phase 3 Trial Results and Strategic Insights Drive Buy Rating for Vidofludimus CalciumOctober 25, 2024 | markets.businessinsider.comImmunic announces outcome of ENSURE programOctober 22, 2024 | markets.businessinsider.comImmunic late-stage program for lead asset to proceed as plannedOctober 22, 2024 | msn.comImmunic Phase 3 MS study advances following positive recommendation from independent committeeOctober 22, 2024 | proactiveinvestors.comImmunic Shares Up 12% on Positive MS Drug AnalysisOctober 22, 2024 | marketwatch.comImmunic Announces Positive Outcome From Interim Futility Analysis Of Phase 3 ENSURE ProgramOctober 22, 2024 | markets.businessinsider.comImmunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple SclerosisOctober 22, 2024 | prnewswire.comFY2024 EPS Estimates for Immunic Decreased by AnalystImmunic, Inc. (NASDAQ:IMUX - Free Report) - Research analysts at Brookline Capital Management reduced their FY2024 earnings per share estimates for shares of Immunic in a report released on Tuesday, October 15th. Brookline Capital Management analyst T. Bussian now expects that the company will eaOctober 18, 2024 | marketbeat.comBrookline Capital Management Comments on Immunic, Inc.'s Q4 2025 Earnings (NASDAQ:IMUX)Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings per share (EPS) estimates for shares of Immunic in a note issued to investors on Tuesday, October 15th. Brookline Capital Management analyst T. Bussian forecasts that the compaOctober 17, 2024 | marketbeat.comShort Interest in Immunic, Inc. (NASDAQ:IMUX) Increases By 14.0%Immunic, Inc. (NASDAQ:IMUX - Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 2,680,000 shares, a growth of 14.0% from the September 15th total of 2,350,000 shares. Based on an average daily volume of 390,200 shares, the short-interest ratio is currently 6.9 days.October 16, 2024 | marketbeat.comRenaissance Technologies LLC Has $323,000 Holdings in Immunic, Inc. (NASDAQ:IMUX)Renaissance Technologies LLC decreased its stake in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 61.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 291,087 shares of the company's stock after selling 456,184 shares during the pOctober 12, 2024 | marketbeat.comImmunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...October 9, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from AnalystsImmunic, Inc. (NASDAQ:IMUX - Get Free Report) has received a consensus recommendation of "Buy" from the seven brokerages that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation toOctober 4, 2024 | marketbeat.comB. Riley Reacts to Immunic’s Update on Clinical Benefits of Vidofludimus CalciumOctober 1, 2024 | msn.comImmunic’s MS Drug Candidate Shows Promising Future: A Comprehensive Buy Rating JustificationSeptember 24, 2024 | markets.businessinsider.comImmunic, Inc. (10VA.F)September 20, 2024 | sg.finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Sees Large Decrease in Short InterestImmunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 2,330,000 shares, a decrease of 7.5% from the August 15th total of 2,520,000 shares. Based on an average daily volume of 307,200 shares, the days-to-cover ratio is presently 7.6 days.September 18, 2024 | marketbeat.comImmunic highlights lead asset's promise in multiple sclerosis at ECTRIMS CongressSeptember 18, 2024 | proactiveinvestors.comImmunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple SclerosisSeptember 18, 2024 | prnewswire.comBuy Rating Affirmed for Immunic, Inc. on Promising MS Drug Developments and Favorable Market PositionSeptember 17, 2024 | markets.businessinsider.comImmunic (NASDAQ:IMUX) Raised to Strong-Buy at EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I upgraded shares of Immunic to a "strong-buy" rating in a research note on Monday.September 17, 2024 | marketbeat.comEF Hutton Initiates Coverage of Immunic (IMUX) with Buy RecommendationSeptember 17, 2024 | msn.comLeerink Partners Likes “Risk/Reward” of Immunic’s CALLIPER ReadoutSeptember 16, 2024 | msn.comImmunic Share Price (IMUX.US)September 15, 2024 | lse.co.ukImmunic stock gets Outperform rating amid optimism for MS drug pipelineSeptember 11, 2024 | uk.investing.comOwning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX),September 11, 2024 | finance.yahoo.comImmunic, Inc. to Post Q3 2024 Earnings of ($0.22) Per Share, Leerink Partnrs Forecasts (NASDAQ:IMUX)Immunic, Inc. (NASDAQ:IMUX - Free Report) - Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for Immunic in a research report issued to clients and investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per shareSeptember 11, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Raised to Strong-Buy at Leerink PartnrsLeerink Partnrs raised Immunic to a "strong-buy" rating in a research note on Monday.September 10, 2024 | marketbeat.com Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address How one pattern has averaged an 85% return per year since the pandemic. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern… Follow this link here and enter your email address to sign up… IMUX Media Mentions By Week IMUX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.890.56▲Average Medical News Sentiment IMUX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼102▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ovid Therapeutics News TherapeuticsMD News Contineum Therapeutics News Cartesian Therapeutics News GH Research News Esperion Therapeutics News MeiraGTx News Organogenesis News Cryoport News Amylyx Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMUX Stock Alerts